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Nevertheless the TNF238.2 polymorphism on the B57.1
haplotype could characterize psoriasis patients with a particular
disease course or be related to an impaired clearance of skin
infections with candida or steptococci, and thus predispose
individuals to the development of psoriasis.
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IgA Antibodies of Linear IgA Bullous Dermatosis Recognize
the 15th Collagenous Domain of BP180
To the Editor:
Linear IgA bullous dermatosis (LAD) is an autoimmune blistering
disease characterized by IgA antibodies against epidermal autoanti-
gens. The antigen for the major type of LAD (lamina lucida type)
was reported to be a 97 kDa protein (Zone et al, 1990;
Dmochowski et al, 1993; Ishiko et al, 1998) or 120 kDa protein
(Marinkovich et al, 1996). The 97 kDa/120 kDa protein was found
to be a degradation product of the 180 kDa bullous pemphigoid
antigen (BP180) (Marinkovich et al, 1997; Pas et al, 1997; Hirako
et al, 1998; Zone et al, 1998). To further characterize the antigenic
sites in LAD, we performed immunoblot studies using various
bacterial recombinant proteins of BP180.
Fourteen sera were collected from clinically typical LAD
patients and showed IgA antibodies reactive with epidermal side
of 1 M NaCl-split skin sections with a titer 1:10±1:40 in
immuno¯uorescence. Ten BP sera and 10 normal sera were
used as controls. A monoclonal antibody D-20, which reacts
with the 120 kDa LAD antigen (Hirako et al, 1998) and an
antiglutathione-S-transferase (GST) rabbit antiserum (Sigma, St.
Louis, MO) were also included as controls. Normal human
epidermal extracts (Dmochowski et al, 1993) and concentrated
supernatant of cultured DJM-1 cells (Hirako et al, 1998) and six
different GST-fusion proteins of BP180, i.e., NC16A, BP1050,
BP963, BP915, BPC15, and BP144, were used as antigen
sources for immunoblotting. The ®rst four fusion proteins were
reported previously (Matsumura et al, 1996; Nie and
Hashimoto, 1999). BP1050, BP963, and BP915 encode N-
terminus, central part, and C-terminus of BP180 extracellular
domain, respectively. By the similar method described pre-
viously (Matsumura et al, 1996; Nie et al, 1999), we prepared
two new recombinant proteins; BPC15 encoding the entire
15th collagenous domain, present just downstream of the
NC16a domain; and BP144 encoding 38 amino acids, which
is further downstream of BPC15, corresponding to the C-
terminal region of BP1050. NC16A, BPC15, and BP144 cover
the entire BP1050, although BP1050 lacks the N-terminus of
the NC16a domain. The constructs for BPC15 and BP144
were con®rmed by DNA sequencing and their correct sizes
(about 46 kDa for BPC15 and about 31 kDa for BP144) as
revealed by anti-GST antiserum in immunoblotting. The
positions of all the recombinant proteins are depicted in Fig 1.
All the results of immunoblotting were summarized in Table I.
In immunoblotting of epidermal extracts, none of the 14 LAD sera
showed speci®c IgA reactivity either with BP180 or with protein
bands in 97 kDa/120 kDa areas, whereas BP180 was detected by
IgG antibodies of 60% BP sera. In contrast, in immunoblotting of
concentrated culture supernatant of DJM-1 cells, IgA antibodies of
12 LAD sera clearly reacted with a 120 kDa protein (Fig 2, panel 1).
This protein was also reacted by IgG antibodies of six BP sera and
the monoclonal antibody D-20.
Because BP1050, BP963, and BP915 roughly cover the
whole extracellular domain of BP180, we ®rst examined IgA
reactivity of the 14 LAD sera with these fusion proteins. Seven
LAD sera reacted clearly with BP1050 (Fig 2, panel 2), and four
sera reacted relatively weakly with BP915 (data not shown),
whereas no LAD sera reacted with BP963. BP1050 is a large
fragment containing 350 amino acids. To further characterize
the epitope(s) within BP1050, we examined IgA reactivity of
LAD sera with three other fusion proteins, i.e., NC16A,
BPC15, and BP144, which in total cover BP1050. Interestingly,
®ve of the 11 LAD sera examined reacted with BPC15 (Fig 2,
panel 3), whereas no sera reacted with either NC16A (Fig 2,
panel 4) or BP144. The monoclonal antibody D-20 also
recognized BP1050 and BPC15, but not other fusion proteins.
As expected, IgG antibodies of the control BP sera reacted with
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Figure 1. Schematic structure of BP180 and the positions of the
recombinant fusion proteins used in this study. An oval in the left
indicates the transmembrane domain, gray columns indicate the collage-
nous domains, and open columns indicate noncollagenous domains of
BP180. Recombinant proteins of C-terminal extracellular region of BP180
are aligned in the corresponding positions of BP180.
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both BP1050 and NC16A, which contain major epitopes for
BP; however, neither IgG nor IgA antibodies of any BP or
normal control sera reacted with BPC15.
These results suggest that major epitope(s) for IgA antibodies
of LAD sera locate(s) in the ®fteenth collagenous domain of
BP180. This ®nding, however, is different from that in the
previous study (Zillikens et al, 1999), which showed that some
LAD sera reacted with NC16a domain. This discrepancy may
be due to differences in subsets of LAD patients between the
two studies; however, our conclusion is supported by the
following observations; (i) the epitope(s) for LAD sera
disappeared by collagenase treatment (Pas et al, 1997); (ii) the
epitope(s) for LAD sera localized in the lamina lucida between
NC16a and C-terminal domain of BP180 indicated by
immunoelectron microscopy (Ishiko et al, 1998); (iii) the
97 kDa LAD antigen is a truncated form of BP180 started
from the amino acid 566, 41 amino acids downstream from the
transmembrane domain, which includes the 15th collagenous
domain (Zone et al, 1998); and (iv) some BP sera reactive with
the 97 kDa LAD antigen reacted with a mid-portion of BP180
extracellular domain,1 or with epitope(s) present in the area
distal from the NC16a domain (Egan et al, 1999).
The most interesting and mysterious issue for LAD is why IgA
antibodies of LAD sera recognize the degraded 97 kDa/120 kDa
LAD antigen (Marinkovich et al, 1996; Pas et al, 1997) and small
fusion proteins, BP1050 and BPC15 (in this study), but not with
the intact BP180. One possible explanation is that the proteins may
not be totally degenerated and may still possess some conformation
even under the presence of SDS, a potent detergent. In this
situation, amino acid sequences in either N-terminus or C-
terminus of BP180 may produce some difference in conformational
structures between the 97 kDa/120 kDa LAD antigen and intact
BP180; however, further studies should be necessary to unravel this
issue.
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Mechanisms other than Shunting are Likely Contributing
to the Pathophysiology of Erythromelalgia
To the Editor:
We read with interest the article by Mùrk et al, ``Microvascular
arteriovenous shunting is a probable pathogenetic mechanism in
erythromelalgia,'' in the April 2000 issue of the Journal of
Investigative Dermatology, in which the authors proposed that the
common pathogenetic mechanism for erythromelalgia is increased
thermoregulatory arteriovenous shunt ¯ow. We have also noted
increased local perfusion during symptoms of heat, redness, and
pain (Sandroni et al, 1999) and have observed a concomitant local
hypoxemia during symptoms, which is consistent with the
hypothesis of shunting.
Wehave been intrigued by the following additional observations in
patients we have studied (Sandroni et al, 1999): (1) the temperature of
the symptomatic extremity occasionally exceeds core temperature;
shunting alone would not explain this ®nding; (2) of the patients
studied, 63% had evidence of small-®ber neuropathy, most
commonly that of a severe postganglionic pseudomotor impairment,
implying that neuropathy is prevalent. Whether the observed
neuropathy led to erythromelalgia, or vice versa, is unclear.
Therefore, we submit that erythromelalgia is a complex disease,
and shunting alone does not explain the ®ndings observed during
symptoms. Increased local metabolism may explain the increase in
local heat, above that of core temperature. The contribution of
small-®ber neuropathy to the syndrome needs to be delineated
further.
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Table I. Summary of immunoblotting using various antigen sources
Recombinant GST-fusion proteins
Cases Epidermala DJM-1b BP1050 BP963 BP915 NC16A BPC15 BP144
1 ± + + ± ± ± + ±
2 ± + + ± + ± + ±
3 ± + + ± + ± + ±
4 ± + + ± ± ± + ±
5 ± + + ± ± ± + ±
6 ± + + ± + ± ± ±
7 ± + + ± ± ± ndc nd
8 ± + ± ± ± ± ± ±
9 ± + ± ± + ± ± ±
10 ± + ± ± ± ± ± ±
11 ± + ± ± ± ± ± ±
12 ± + ± ± ± ± ± ±
13 ± ± ± ± ± ± nd nd
14 ± ± ± ± ± ± nd nd
Total 0 12 7 0 4 0 5 0
D-20 ± + + ± ± ± + ±
GST-Ab not done not done + + + + + +
Normal(IgG) 0/10 0/10 0/10 0/10 0/10 0/10 0/10 0/10
Normal(IgA) 0/10 0/10 0/10 0/10 0/10 0/10 0/10 0/10
BP(IgG) 6/10 6/10 10/10 0/10 0/10 10/10 0/10 0/10
BP(IgA) 0/10 0/10 0/10 0/10 0/10 0/10 0/10 0/10
aEpidermal, epidermal extracts; the results show the reactivity with BP180.
bDJM-1, concentrated culture supernatant of DJM-1 cells. (+) means that the LAD serum reacted with the 120 kDa LAD antigen.
cnd, not done due to shortage of the serum.
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